In-depth Analysis and Forecast Of The Huntingtons Disease Market 2024 On The Global As Well As Regional Level
"The
Latest Research Report OpportunityAnalyzer: Huntingtons Disease -
Opportunity Analysis and Forecast to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Huntingtons Disease Market
Huntingtons
Disease (HD) is a rare, autosomal-dominant, neurodegenerative
disorder, characterized by impaired motor control, cognitive
dysfunction, behavioral changes, and mood disorders. Approved
treatments for HD across the 7MM are extremely limited, consisting of
only two symptomatic treatments, tetrabenazine and tiapride, which
are both approved for the treatment of HD-associated chorea. Other
treatment options contributing to the HD market are off-label
symptomatic drugs, many of which are widely genericized throughout
the 7MM. Four late-stage pipeline drugs, two symptomatic treatments
(SD-809 and pridopidine) and two potential DMDs (RP103 and PBT2) are
expected to launch in the US and 5EU markets during the forecast
period, and will be a source of significant growth in the HD market.
It is anticipated that SD-809 and pridopidine will also launch in
Japan within the forecast period.
Highlights
Key Questions Answered
-
The HD market has been dominated by tetrabenazine and tiapride
(approved in Germany, Italy, and Spain; off-label in France and
Japan) for many years, with little approved therapeutic options
available in the 7MM. New classes of drugs are anticipated to reach
the market within the forecast period. How will these change the
market overall during the forecast period? Will tetrabenazine
maintain market dominance in 2024?
-
The current late stage HD pipeline is varied, with first-in-class
drugs in development with innovative modes of action. Which of these
will have the biggest impact on the market? What strategies are
developers undertaking to penetrate this chronically underserved
market? Will these fulfil any unmet needs?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/774306
Key Findings
-
The main driver of growth in the HD market will be the introduction
of premium-priced disease-modifying drugs and improved symptomatic
therapies over the forecast period. The launch of these treatments
will act as a stimulant for growth in this chronically underserved
market.
-
Significant barriers to growth in the HD market will be the high cost
of novel treatments and potential issues surrounding reimbursement,
which will limit the use of more expensive drugs. Patients who have
an acceptable level of symptomatic control with currently marketed
drugs could result in limited treatment costs for HD.
-
The arrival of new therapies across the 7MM will increase treatment
rates and provide alternative options for many patients.
-
The largest unmet needs in the HD market are the development of
efficacious disease-modifying drugs and symptomatic treatments. In
addition, the identification of a robust HD biomarker for monitoring
disease progression, as well as determining the effects of
therapeutic interventions, is a significant unmet need in this field.
Scope
-
Overview of HD, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and treatment guidelines.
-
Annualized HD market revenue, annual cost of therapy and treatment
usage pattern data from 2014 and forecast for ten years to 2024.
-
Key topics covered include market characterization, unmet needs, R&D
and clinical trials assessment, late stage clinical trial analysis
and implications for the HD therapeutics market.
-
Pipeline analysis: focus on the six late-stage pipeline HD drugs
discussing emerging trends as well as overview of earlier phase
drugs.
-
Analysis of the current and future market competition in the global
HD therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global HD therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global HD therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global HD therapeutics market from 2014-2024.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Send
An Enquiry Request @
Table of Contents
1
Table of Contents 9
1.1
List of Tables 14
1.2
List of Figures 17
2
Introduction 18
2.1
Catalyst 18
2.2
Related Reports 18
3
Disease Overview 19
3.1
Etiology and Pathophysiology 19
3.1.1
Etiology 19
3.1.2
Pathophysiology 22
3.2
Quality of Life 29
3.3
Symptoms 29
3.4
Diagnosis and Disease Monitoring 30
4
Epidemiology 35
4.1
Disease Background 35
4.2
Risk Factors and Complications 36
4.3
Global Trends 36
4.3.1
Diagnosed Prevalence of HD-7MM 36
4.4
Forecast Methodology 39
4.4.1
Sources Used 42
4.4.2
Sources Not Used 44
4.4.3
Forecast Assumptions and Methods 45
4.5
Epidemiological Forecast of HD (2014-2024) 47
4.5.1
Diagnosed Prevalent Cases 47
4.5.2
Diagnosed Prevalent Cases of HD by Age at Onset 59
4.5.3
Diagnosed Prevalent Cases of Adults with Juvenile-Onset HD that
Progressed to Adulthood, Ages 20 Years 60
4.6
Discussion 62
4.6.1
Epidemiological Forecast Insight 62
4.6.2
Limitations of the Analysis 63
4.6.3
Strengths of the Analysis 64
5
Current Treatment Options 65
5.1
Overview 65
5.1.1
Antipsychotic Drugs 67
5.1.2
Antidepressant Drugs 73
5.1.3
Benzodiazepines 77
5.1.4
Anticonvulsant Drugs 81
5.1.5
Antiparkinson Drugs 85
5.1.6
Botulinum Toxin Type A 87
5.2
Product Profiles-Major Brands 89
5.2.1
Xenazine (Tetrabenazine) 89
5.2.2
Tiapride 97
6
Unmet Needs Assessment and Opportunity Analysis 102
6.1
Overview 102
6.2
Disease-Modifying Drugs 103
6.2.1
Unmet Need 103
6.2.2
Gap Analysis 104
6.2.3
Opportunity 107
6.3
Efficacious Cognitive Enhancers 108
6.3.1
Unmet Need 108
6.3.2
Gap Analysis 109
6.3.3
Opportunity 110
6.4
Improved Symptomatic Treatments 111
6.4.1
Unmet Need 111
6.4.2
Gap Analysis 112
6.4.3
Opportunity 114
6.5
Identification of Disease Biomarker 115
6.5.1
Unmet Need 115
6.5.2
Gap Analysis 116
6.5.3
Opportunity 117
6.6
Increased Knowledge of HD Pathogenesis 118
6.6.1
Unmet Need 118
6.6.2
Gap Analysis 119
6.6.3
Opportunity 119
6.7
More Comprehensive Treatment Guidelines 119
6.7.1
Unmet Need 119
6.7.2
Gap Analysis 121
6.7.3
Opportunity 122
6.8
Novel Formulations 122
6.8.1
Unmet Need 122
6.8.2
Gap Analysis 123
6.8.3
Opportunity 124
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment